Who We Fund

Investing in Industry and Academic Research

 

We have awarded more than $20 million in brain tumor research funding to world-renowned research investigators and physician-scientists from 42 institutions. We partner with medical research centers, early-stage biotechnology companies and large multi-national pharmaceutical companies.  These partners all share our vision of driving translational research to move treatments as fast as possible from basic discovery to the clinic. 

For more information on our current projects, please click here.

Investments in Industry

  • Agios

    ABC2’s investment provided the support Agios needed to move its cancer metabolism project into brain cancer. Prior to our involvement, Agios focused exclusively on leukemia research.

  • Exosome Diagnostics

    ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.

  • Genentech

    ABC2 funded Genentech’s early stage research and clinical trial work to test and develop the drug Avastin to treat brain cancer patients.

  • Regulus Therapeutics

    Regulus is now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.

  • Tocagen

    ABC2 was the first non-profit organization to fund Tocagen, a biotech company that was able to then go onto raise additional funding for their groundbreaking therapy.

  • Duke Medicine

    This collaboration establishes a missing link between the biopharmaceutical industry’s efforts to produce life-saving drugs and theoretical knowledge at the cutting edge of scientific inquiry.

Brain Tumor Research Grants

  • UCLA

    ABC2 is funding the development of a clinical trial to determine if retinoic acid -- Accutane -- might be an effective brain cancer treatment for patients with IDH gene mutations.

  • Johns Hopkins

    We are funding a clinical trial at Johns Hopkins to test whether mebendazole, a drug already approved by the FDA to fight

  • Mayo Clinic / T-Gen

    ABC2’s investment helps move forward a novel personalized medicine trial for glioblastoma patients led by Mayo Clinic, one of the leading clinical centers, and TGen, a cutting edge genomics lab.

  • UCSF

    ABC2 is funding a UCSF project to understand the effects of temozolomide on low-grade gliomas.

  • DIPG

    ABC2’s investment and scientific guidance is helping to advance the work of an international consortium working on a treatment for a rare pediatric brain tumor called diffuse intrinsic pontine glioma (DIPG).

  • Exosome Diagnostics

    ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.

Share |

Join us in our fight for a cure!

Twitter